The JOURNEY trial, a randomized, open-label study, evaluates a single intravitreal injection of VOY-101. By utilizing a fellow-eye controlled design, investigators aim to isolate the therapy's impact on lesion size while accounting for individual genetic and environmental variables. VOY-101 functions by encoding a protective variant of Complement Factor H, seeking to restore pathway regulation in patients suffering from the advanced form of dry age-related macular degeneration.
In section Releases
Perceive Bio Hits Enrollment Milestone for GA Gene Therapy Trial
Perceive Biotherapeutics has surpassed its recruitment goal for the Phase 2a JOURNEY study, testing the gene therapy VOY-101 for geographic atrophy. With 94 eyes enrolled across 47 participants, the company is now positioned to deliver topline 15-month data for the potential one-time treatment by late 2027.
Simultaneously, the South San Francisco-based company has expanded its leadership, appointing Tony Gibney to its Board of Directors. Gibney, a veteran executive with a history at Iveric Bio and Aura Biosciences, brings extensive experience in navigating the regulatory and strategic landscape of complement-targeted therapies. His appointment coincides with a critical period as the company prepares for its upcoming clinical readout and potential long-term development of its ocular pipeline.
Comments (0)
No comments yet. Be the first!